Effect of N- -Phenylpropyl-N-benzyloxy Acetamide (W-1372) and of Clofibrate on the Lipids of Normal and Hypercholesteremia Rats

Berger, F. M.; Douglas, J. F.; Lu, Guangrong; Ludwig, B. J.

doi:10.3181/00379727-132-34200

Cited by 7 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clofibrate and especially procetofene behave differently since they variably influence the lipid content of the liver and cause hepato megaly within a wide range of doses -see also the articles on clofibrate by Azarnoff et al [2], Berger et al [3] and Grafnetter et al [14]. This difference becomes more evident by comparing the effect on liver weight mani fested by equiactive doses on blood Ch (e.g., 10 mg/kg of LR 19731 and 100 mg/kg of clo fibrate cause a 50% decrease of Ch and a 4 and 22% increase, respectively, in the liver weight of normolipemic adult rats treated five times in 4 days).…”

Section: Discussionmentioning

confidence: 99%

Metabolic Disorders Associated with Hyperlipemia: Activity of an Extremely Potent Hypolipemic Agent (LR 19731)

Fregnan¹,

Frigerio²,

Porta³

1981

Pharmacology

View full text Add to dashboard Cite

LR 19731 [4-β-chlorophenyl-5-β-(N’-phenyl)piperazinoethyl-l,3-dioxolin-2-one] lowers the plasma cholesterol and triglyceride levels of rats in several experimental conditions after single or repeated treatments, while it is scarcely active on liver lipids. The compound is especially effective in reducing plasma cholesterol in a dose-related manner both in normolipemic and hyperlipemic rats. The minimal effective dose (after five oral treatments in 4 days to normolipemic rats) is as low as 3 mg/kg, the ED₅₀ is 11.3 mg/kg, while the maximal effective dose capable of completely suppressing plasma cholesterol is 100 mg/kg. Surgical removal of the thyroid gland does not influence its activity. At its ED₅₀ the compound does not cause hepatomegaly, accumulation of desmosterol in plasma and liver. Under the same experimental conditions clofibrate presents a poor dose-response correlation on plasma lipids and generally appears at least 10 times less active than LR 19731 on cholesterol but more effective on liver weight. The experiments of general pharmacology indicate that LR 19731 does not affect central and peripheral nervous functions, does not influence the cardiovascular system or cause skeletal muscle relaxation, hypothermia, analgesia, and does not possess anti-inflammatory properties up to a dose of about 100 mg/kg.

show abstract

Section: Discussionmentioning

confidence: 99%